Sanofi

This study will monitor the safety of the MenQuadfi vaccine in 706 people aged 6 weeks to 55 years in South Korea. Researchers will track side effects like injection-site reactions and serious adverse events as the vaccine is used in real-world clinics. The goal is to confirm the…

This study is checking the safety of a high-dose flu vaccine called Efluelda in adults aged 65 and older in South Korea. About 670 participants will receive one shot and be monitored for side effects for about a month. The goal is to see how often reactions like injection site pa…

This study is checking the safety of a high-dose flu vaccine called Efluelda Tetra in adults aged 65 and older in South Korea. About 670 participants will receive one dose and be monitored for side effects for about a month. The goal is to see how often reactions like injection s…

This registry will follow 350 COPD patients starting dupilumab (Dupixent) to see how well it works and how safe it is in real life. Researchers will track flare-ups, lung function, and quality of life over 24 months, comparing them to similar patients not on the drug. The goal is…

This study tests the safety of a drug called belumosudil in 26 Indian patients aged 12 and older who have chronic graft-versus-host disease (cGVHD), a complication after a stem cell transplant. Participants take the drug for up to 24 weeks, and doctors monitor for side effects an…

This Phase 3 trial tests itepekimab, an injected antibody, in 20 Japanese adults with chronic sinusitis and nasal polyps that are not well-controlled despite surgery or steroids. The study measures changes in polyp size and nasal congestion over 52 weeks. It aims to see if the dr…

This study will observe how many eligible infants in Czechia receive nirsevimab, a monoclonal antibody that helps prevent RSV, during their first RSV season. Researchers will survey parents of about 250 infants born between April 2025 and March 2027 to understand immunization rat…